BRAF and melanoma: Mutant BRAF and DDR1/2 co‐targeting in the three melanoma cell lines plated on FRC‐ or MAF‐derived ECMs decreased levels of phosphorylated Rb, E2F1, and survivin, and induced caspase‐3 cleavage (Figs 4D and EV3A and B).